New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
10:53 EDTWMC, CTRX, IMGN, ITW High option volume stocks: ITW CTRX WMC LQD IMGN
News For ITW;CTRX;WMC;IMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
16:31 EDTIMGNOn The Fly: Closing Wrap
Subscribe for More Information
13:30 EDTIMGNImmunoGen downgraded to Market Perform from Outperform at Leerink
Leerink downgraded ImmunoGen to Hold following disappointing MARIANNE trial results.
13:16 EDTIMGNImmunoGen downgraded to Hold from Buy at Jefferies
Subscribe for More Information
12:27 EDTIMGNOn The Fly: Midday Wrap
Subscribe for More Information
09:28 EDTIMGNOn The Fly: Pre-market Movers
Subscribe for More Information
05:36 EDTIMGNImmunoGen reports Phase III MARIANNE study met non-inferiority endpoint
Subscribe for More Information
December 11, 2014
07:47 EDTWMCUBS to hold a conference
Subscribe for More Information
December 10, 2014
15:14 EDTIMGNImmunoGen volatility at high end of historic range
Subscribe for More Information
08:35 EDTCTRXCatamaran management to meet with SunTrust
Subscribe for More Information
December 8, 2014
11:30 EDTCTRXLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
10:00 EDTITWOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
07:56 EDTITWIllinois Tool Works price target raised to $110 from $95 at Stifel
Subscribe for More Information
07:07 EDTITWIllinois Tool Works upgraded to Buy from Accumulate at Global Hunter
Global Hunter upgraded Illinois Tool Works to Buy based on strong 2015 guidance, shareholder returns, and operating leverage. Price target raised to $111 from $92.
December 7, 2014
12:53 EDTIMGNImmunoGen announces 'encouraging' IMGN529 clinical data
ImmunoGen announced the presentation of encouraging clinical findings with its IMGN529 experimental therapy for B-cell malignancies at the American Society of Hematology annual meeting. These include objective responses at doses that were generally well tolerated. ImmunoGenís IMGN529 is a potential new treatment for DLBCL and other non-Hodgkin lymphoma, NHL, subtypes. An ADC, it comprises an antibody that targets CD37, found on B-cell malignancies, with the potent cancer cell-killing agent, DM1, attached. The antibody serves to deliver the DM1 specifically to B cells to kill them and, based on preclinical research, also contributes anticancer activity. IMGN529 is currently in the dose-finding portion of a Phase I clinical trial, which assesses increasing doses of this experimental therapy in new groups of patients with relapsed/refractory NHL. Findings with the first doses evaluated were reported previously.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use